Philip Niles, MD, MBA

Explore how high-dose aflibercept and dual-pathway faricimab boost anti-VEGF durability, targeting VEGF-A and Ang-2 for better retinal outcomes.

Clinicians tailor treat-and-extend anti-VEGF care, using newer agents to control faster and stretch injections to 20 weeks, reducing burden.

Learn how next‑gen anti‑VEGF therapies rapidly control wet AMD, DME and vein occlusion, cutting injections and protecting vision.

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing cuts clinic burden, affects costs, and reveals key evidence gaps for AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, provide insight on unmet needs and future directions for the treatment of wet AMD and DME.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; and Kevin U. Stephens, Sr., JD, MD, explore the role of faricimab in the current treatment landscape for wet AMD.

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, comment on safety and cost considerations for the uptake of anti-VEGF biosimilars such as ranibizumab and discuss the impact on the future treatment landscape for wet AMD.

Nicholas G. Anderson, MD, explores the use of a novel port delivery system with ranibizumab for the treatment of wet AMD.

Philip Niles, MD, MBA; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, discuss the clinical and economic implications of a delay in therapy for wet AMD and DME.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Nicholas G. Anderson, MD; and Jim Kenney, RPh, MBA, comment on managing the utilization of anti-VEGF agents for wet AMD and DME, including the impact of step edits on care.

Nicholas G. Anderson, MD, shares factors to consider when selecting an anti-VEGF agent for treatment of wet AMD and DME.

Philip Niles, MD, MBA, leads a discussion on treatment approaches that are utilized with anti-VEGF agents in wet AMD and DME, including payer considerations for approaches such as treat and extend.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; and Kevin U. Stephens, Sr., JD, MD, provide insight on the anti-VEGF treatment landscape and options for patients with wet AMD and DME.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, review goals of therapy for patients with wet age-related macular degeneration (AMD) and discuss a health plan perspective for the management of therapy.

Kevin U. Stephens, Sr., JD, MD, leads a discussion exploring the key drivers of cost for patients with wet age-related macular degeneration (AMD).

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life.

Philip Niles, MD, MBA, and Nicholas G. Anderson, MD, define wet age-related macular degeneration (AMD) and review clinical manifestations of the disease.